Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P-TET
- Development stage
- Preclinical
- Lead developer
- NanoPharmaceuticals
- Modality
- Nanoparticles → Drug Delivery Systems
01
Overview
P-TET is a preclinical-stage nanoparticle drug candidate under development by Nano-Pharmaceuticals for the treatment of inflammatory skin diseases, specifically psoriasis and rosacea. As a nanoparticle formulation, P-TET is designed to target localized inflammation in the skin, though its specific molecular targets and detailed mechanism of action have not been publicly disclosed. The candidate is currently in the initial phases of preclinical planning and development.
Beyond the preview
Go deeper on P-TET.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P-TET.